Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania
Study Details
Study Description
Brief Summary
The objectives of this study are to determine whether this treatment may be useful for reducing cannabis consumption; reducing symptoms of bipolar mania; and weight mitigation therapy for individuals on psychopharmacotherapy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
The purpose of this research study is to study the effects (both good and bad) of combining medicines, called quetiapine and topiramate, for treating your symptoms, and other children and adolescents' symptoms, of bipolar mania (an illness with periods of elation, excessive excitement, irritability, high energy, racing thoughts, poor sleep, poor judgment, reckless behavior). It is estimated that 1% of the population of adolescents in the United States has bipolar disorder. The purpose of this research study is also to study the effects (both good and bad) of combining the same two medicines, quetiapine and topiramate, for reducing your use, and other children and adolescents' use, of cannabis (commonly referred to as "pot"). It is estimated that 30.5% of adolescents in the United States have used cannabis at least once in their lifetime. Additionally, the purpose of this research is to look at how bipolar disorder and cannabis use effects brain chemicals and function.
Quetiapine (marketed under the brand name Seroquel) has been approved by the FDA since 1997 to help adults who suffer from schizophrenia (an illness of feeling, thought, perception and behavior). On January 12, 2004, the FDA approved quetiapine for the treatment of bipolar symptoms in adults. As of December 2009, Quetiapine has now been approved by the FDA for use in adolescents (13-17 years of age) for the treatment of schizophrenia and for the treatment of manic episodes associated with bipolar I disorder in children and adolescents (10-17 years of age). Bipolar disorder is an illness characterized by recurrent mood swings including mania (i.e., periods of elation, excessive excitement, irritability, high energy, racing thoughts, poor sleep, poor judgment, reckless behavior) and clinical depression (i.e., a depressed mood, loss of interest in activities and disruption of sleep, appetite and energy). This study is being carried out to see if quetiapine is effective and safe for treatment of children and adolescents who have the symptoms of bipolar mania. This study is also being carried out to see if quetiapine, in combination with topiramate, will further reduce bipolar mania and reduce cannabis use.
As of December 2, 2009, the US Food and Drug Administration (FDA) approved SEROQUEL (quetiapine fumarate) tablets for the treatment of schizophrenia in adolescents (13-17 years of age) as monotherapy, and for the acute treatment of manic episodes associated with bipolar I disorder in children and adolescents (10-17 years of age), both as monotherapy and as an adjunct to lithium or divalproex.
Topiramate (marketed under the brand name Topamax) is approved by the U.S. FDA for the prevention of migraine headaches in adults. The FDA has also approved topiramate for epilepsy (a seizure disorder) and for use as adjunctive therapy (meaning in combination with other medicines) for partial onset seizures in adults. Topiramate is not approved by the FDA for use in adults or for use in children and adolescents who have bipolar disorder. This study is being done to see if topiramate, in combination with quetiapine, will reduce bipolar mania and reduce cannabis use.
The FDA has declared research studies with MRI field strengths up to and including 8 Tesla (a measure of field strength) as non-significant risk. This research study uses an MRI with a field strength of 4 Tesla.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Placebo Comparator: Quetiapine and Placebo Quetiapine and Placebo |
Drug: Quetiapine and placebo
placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).
Other Names:
|
| Active Comparator: Quetiapine and Topiramate Quetiapine and Topiramate |
Drug: Quetiapine and Topiramate
topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).
|
Outcome Measures
Primary Outcome Measures
- Change in Joints Per Week [16 weeks]
Change in timeline follow-back self-reported of joint equivalents per week from baseline to 16 weeks.
- Change in Percent Days of Cannabis Use Per Week [16 weeks]
Change in percent days of cannabis use per week from baseline to week 16.
Eligibility Criteria
Criteria
Inclusion/Exclusion Criteria Inclusion Criteria: To be included, all subjects must…
-
have an authorized parent/legal guardian who understands the nature of the study and who provides written informed consent if the study subject is younger than 18 years of age. Additionally, each subject must provide assent to the study;
-
be fluent in English;
-
be 12 to 21 years of age, inclusive;
-
be using a medically accepted means of contraception (i.e., oral contraceptives and barrier methods (diaphragm or condom), medroxyprogesterone acetate injectable suspension, abstinence) if female and of menarche. Oral contraceptives alone are not acceptable means of contraception because concomitant use of topiramate and low estrogen oral contraceptive pills may lead to oral contraceptive failure;
-
have a diagnosis of bipolar I disorder in a current manic or mixed episode, in addition to a cannabis use disorder (which includes abuse or dependence) within 28 days prior to screening, as determined by the WASH-U-KSADS;
-
have an initial YMRS total score of >16 at screening and baselines;
-
use cannabis a minimum of twice per week on average during the 28 days prior to screening.
Exclusion Criteria: Subjects will not be eligible for participation if they…
-
have a known history of mental retardation;
-
are acutely intoxicated, and thus impaired;
-
have manic or depressive symptoms resulting entirely from acute medical illness or acute intoxication or withdrawal from drugs or alcohol, as determined by medical evaluation and rapid symptom resolution;
-
have clinically significant alcohol or other drug withdrawal symptoms, as determined by vital signs, The Clinical Institute Withdrawal Assessment for Alcohol Scale - Revised (CIWA-Ar)24, and physician interview;
-
have any unstable medical or neurological illness as determined by a study physician;
-
have laboratory abnormalities >3 times upper limits of established normal values;
-
as females, have a positive serum (screening and week 16) or urine pregnancy test (at baseline and weeks 1-16), are lactating, or are not practicing a reliable form of birth control;
-
have a history of nephrolithiasis, since topiramate has been associated with an elevated risk of kidney stones;
-
require concurrent treatment with mood stabilizers, anticonvulsants, or antidepressants
-
require concurrent treatment with carbonic anhydrase inhibitors.
-
have significant suicidal ideation
-
have been treated for a substance use disorder during 28 days prior to screening or are court-ordered to treatment for substance use to ensure that, if we detect a change in use with topiramate treatment, it is likely not due to these other confounding factors that might influence substance use. Peer support groups are not considered treatment for substance use. Patients can be enrolled into the study that are already enrolled in a court ordered substance treatment, for at least 1 month prior to study enrollment, if they still meet the minimum cannabis use criterion.
-
have been diagnosed or treated for an eating disorder, to make sure any weight loss does not contribute to an already underlying condition
-
have a family history of glaucoma, since topiramate has been associated with an elevated risk of glaucoma;
-
have a history of non-response or hypersensitivity to quetiapine or topiramate;
-
if scanning, have claustrophobia and/or contraindicated for magnetic resonance scanning (i.e. intraocular metallic objects, braces, cochlear implants, pacemakers, or other electrical, mechanical, or magnetically activated implants); and
-
if scanning, have a history of significant head trauma (i.e. injury resulting in loss of consciousness for greater than five minutes).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Cincinnati Medical Center | Cincinnati | Ohio | United States | 45219-0516 |
Sponsors and Collaborators
- University of Cincinnati
- National Institute on Drug Abuse (NIDA)
Investigators
- Principal Investigator: Melissa P DelBello, MD, University of Cincinnati
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NIDA
- R01DA022221
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Quitiapine + Placebo | Quetiapine + Topiramate |
|---|---|---|
| Arm/Group Description | Quetiapine + Placebo quetiapine + placebo: placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day). | Quetiapine + Topiramate Quetiapine + Topiramate: topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day). |
| Period Title: Overall Study | ||
| STARTED | 37 | 38 |
| COMPLETED | 21 | 18 |
| NOT COMPLETED | 16 | 20 |
Baseline Characteristics
| Arm/Group Title | Quitiapine + Placebo | Quetiapine + Topiramate | Total |
|---|---|---|---|
| Arm/Group Description | Quetiapine + Placebo quetiapine + placebo: placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day). | Quetiapine + Topiramate Quetiapine + Topiramate: topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day). | Total of all reporting groups |
| Overall Participants | 37 | 38 | 75 |
| Age (Count of Participants) | |||
| <=18 years |
37
100%
|
38
100%
|
75
100%
|
| Between 18 and 65 years |
0
0%
|
0
0%
|
0
0%
|
| >=65 years |
0
0%
|
0
0%
|
0
0%
|
| Age (years) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [years] |
17.1
(2.1)
|
17.7
(2.1)
|
17.4
(0.2)
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
18
48.6%
|
20
52.6%
|
38
50.7%
|
| Male |
19
51.4%
|
18
47.4%
|
37
49.3%
|
| Region of Enrollment (participants) [Number] | |||
| United States |
37
100%
|
38
100%
|
75
100%
|
Outcome Measures
| Title | Change in Joints Per Week |
|---|---|
| Description | Change in timeline follow-back self-reported of joint equivalents per week from baseline to 16 weeks. |
| Time Frame | 16 weeks |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Quitiapine and Placebo | Quetiapine and Topiramate |
|---|---|---|
| Arm/Group Description | Quetiapine and Placebo Quetiapine and placebo: placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day). | Quetiapine and Topiramate Quetiapine and Topiramate: topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day). |
| Measure Participants | 37 | 38 |
| Mean (Standard Deviation) [joints] |
-10.1
(27.2)
|
-10.7
(18.4)
|
| Title | Change in Percent Days of Cannabis Use Per Week |
|---|---|
| Description | Change in percent days of cannabis use per week from baseline to week 16. |
| Time Frame | 16 weeks |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Quitiapine and Placebo | Quetiapine and Topiramate |
|---|---|---|
| Arm/Group Description | Quetiapine and Placebo Quetiapine and placebo: placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day). | Quetiapine and Topiramate Quetiapine and Topiramate: topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day). |
| Measure Participants | 37 | 38 |
| Mean (Standard Deviation) [cannabis use] |
-29.9
(41.1)
|
-43.5
(38.1)
|
Adverse Events
| Time Frame | Over a period of 3 years | |||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | Quitiapine + Placebo | Quetiapine + Topiramate | ||
| Arm/Group Description | Quetiapine + Placebo quetiapine + placebo: placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day). | Quetiapine + Topiramate Quetiapine + Topiramate: topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day). | ||
All Cause Mortality |
||||
| Quitiapine + Placebo | Quetiapine + Topiramate | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
| Quitiapine + Placebo | Quetiapine + Topiramate | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 6/37 (16.2%) | 5/38 (13.2%) | ||
| Psychiatric disorders | ||||
| Hospitalization | 5/37 (13.5%) | 4/38 (10.5%) | ||
| Increased Suicidal Ideation | 0/37 (0%) | 1/38 (2.6%) | ||
| Reproductive system and breast disorders | ||||
| Pregnancy | 1/37 (2.7%) | 0/38 (0%) | ||
Other (Not Including Serious) Adverse Events |
||||
| Quitiapine + Placebo | Quetiapine + Topiramate | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 30/37 (81.1%) | 23/38 (60.5%) | ||
| General disorders | ||||
| Difficulty falling asleep | 20/37 (54.1%) | 12/38 (31.6%) | ||
| Difficulty staying asleep | 20/37 (54.1%) | 12/38 (31.6%) | ||
| Excitement | 0/37 (0%) | 5/38 (13.2%) | ||
| Dry Mouth | 30/37 (81.1%) | 23/38 (60.5%) | ||
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Melissa P. DelBello, MD |
|---|---|
| Organization | University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience |
| Phone | 513-558-2989 |
| Melissa.DelBello@uc.edu |
- NIDA
- R01DA022221